X0306 4 2022-10-03 0 0001840574 Verve Therapeutics, Inc. VERV 0001864112 Kathiresan Sekar C/O VERVE THERAPEUTICS 500 TECHNOLOGY SQUARE, SUITE 901 CAMBRIDGE MA 02139 1 1 0 0 Chief Executive Officer Common Stock 2022-10-03 4 M 0 50000 1.39 A 367839 D Common Stock 2022-10-03 4 S 0 28911 33.0157 D 338928 D Common Stock 2022-10-03 4 S 0 11185 34.1296 D 327743 D Common Stock 2022-10-03 4 S 0 9904 34.9723 D 317839 D Common Stock 240997 I Kathiresan Family 2021 Irrevocable Trust Common Stock 80997 I Sekar Kathiresan 2021 Irrevocable Trust Stock Option (right to buy) 1.39 2022-10-03 4 M 0 50000 0.00 D 2029-04-14 Common Stock 50000 138995 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2022. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.59 to $33.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), and (4) of this Form 4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.59 to $34.59, inclusive. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.61 to $35.50, inclusive. The remaining shares underlying this option, which was granted on April 15, 2019, vest in equal monthly installments until March 25, 2024. /s/ Andrew Ashe, Attorney-in-Fact for Sekar Kathiresan 2022-10-05